Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer
with HER2 Mutation.
10.3779/j.issn.1009-3419.2025.106.22
- Author:
Jinyu YU
1
;
Baoshan CAO
1
Author Information
1. Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:English Abstract
- Keywords:
Human epidermal growth factor receptor 2;
Lung neoplasms;
Mutation;
Targeted therapy
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/pathology*;
Lung Neoplasms/pathology*;
Receptor, ErbB-2/metabolism*;
Mutation;
Molecular Targeted Therapy;
Protein Kinase Inhibitors/therapeutic use*;
Antineoplastic Agents/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(8):612-620
- CountryChina
- Language:Chinese
-
Abstract:
Human epidermal growth factor receptor 2 (HER2) mutations play a role as a driver gene in non-small cell lung cancer (NSCLC). Patients with advanced NSCLC harboring HER2 mutations exhibit poor responses to conventional chemotherapy and immunotherapy, hence targeted therapies against HER2 are under extensive investigation. This review analyzes the biological characteristics of HER2, an overview of clinical trials for targeted therapy drugs, including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate, and research directions for drug resistance in NSCLC. Currently, Pyrotinib and Trastuzumab deruxtecan have been approved for the treatment of advanced NSCLC with HER2 mutations, suitable for patients who have failed standard therapy, which is far from meeting the clinical demands. Novel selective HER2 TKIs are gradually emerging. Future exploration trends are gradually shifting from single drugs to combination strategies, and are exploring more precise selection strategies as well as research on resistance mechanisms. These studies will provide a theoretical basis for clinical treatment strategies for advanced NSCLC with HER2 mutations, promoting the development of personalized therapy.
.
